Short Description
The Laboratory of Molecular Immunology focuses on understanding the molecular and cellular mechanisms that regulate the function of the immune system under both physiological and pathological conditions, with particular emphasis on cancer immunology and virus-host interactions. The research activity integrates advanced molecular, cellular and immunological approaches, aiming at the development of innovative diagnostic and therapeutic applications for diseases associated with immune system dysfunction.
- Molecular and cellular mechanisms regulating immune responses
- Cancer immunology and development of immunotherapeutic approaches – Design and application of DNA vaccines
- Bioactive natural compounds and probiotic microorganisms with immunomodulatory and anticancer properties
- Nanobiotechnological applications in cancer diagnosis and therapy
- Virus-host interactions and the role of viral proteins (e.g. SARS-CoV-2) in immune responses and immunodiagnosis
- 2021-2025: “BIOACTIVESCREEN: Bioactivescreen Research Infrastructure in Northern Greece: identification of endemic aromatic plant-derived bioactive compounds of high-added value”. Hellenic Foundation for Research & Innovation. HFRI-FM17C3-2007. Budget for DMBG/DUTh: 1.440.000 €.
2020-2021: National Strategic Reference Framework (NSRF-GSRT) 2014-2020 EDBM103: Operational Programme “Human Resources Development, Eduction and Lifelong Learning”, for “Supporting researchers with an emphasis on young researchers – EDBM 103”, title: “Biosynthesis of selenium nanoparticles in probiotic lactobacilli and investigation of thier anticancer and immunoenhancing properties”. Budget for DUTH: 45.545,50 €.
- ΕΛΙΔΕΚ 2020 Δράση «1η προκήρυξη ερευνητικών έργων ΕΛ.ΙΔ.Ε.Κ. για την ενίσχυση μελών ΔΕΠ και ερευνητών/τριών και την προμήθεια ερευνητικού εξοπλισμού μεγάλης αξίας – Β’ φάση». Τίτλος: «Ερευνητική υποδομή BioActiveScreen στη Βόρεια Ελλάδα: Ταυτοποίηση βιοενεργών φυτοχημικών ουσιών υψηλής προστιθέμενης αξίας από ενδημικά αρωματικά φυτά (BioActiveScreen)». Χρονική διάρκεια: 2021-2024. Προϋπολογισμός για το ΔΠΘ 1.440.000,- ευρώ.
- ΕΣΠΑ 2014-2020 Άξονας προτεραιότητας «Βελτίωση της ποιότητας και αποτελεσματικότητας του εκπαιδευτικού συστήματος» του Επιχειρησιακού Προγράμματος «Ανάπτυξη Ανθρώπινου Δυναμικού, Εκπαίδευση & Δια Βίου Μάθηση 2014-2020» στο πλαίσιο της Πράξης «Υποστήριξη ερευνητών με έμφαση στους νέους ερευνητές – κύκλος Β’ (ΕΔΒΜ103), με τίτλο: «Βιοσύνθεση νανοσωματιδίων σεληνίου σε προβιοτικούς λακτοβακίλλους και διερεύνηση της αντικαρκινικής και ανοσοενισχυτικής τους δράσης». Προϋπολογισμός έργου: 45.545,50 ευρώ. Χρονική διάρκεια: 10/03/2020 έως 25/12/2021.
- Mouzakis A, Petrakis V, Tryfonopoulou E, Panopoulou M, Panagopoulos P, Chlichlia K. Mechanisms of immune evasion in HIV-1: the role of virus-host protein interactions. Curr Issues Mol Biol 2025, 47(5): 367.
- Aindelis G, Glaros V, Fragoulis K, Mouchtari A, Spyridopoulou K, Chlichlia K. Colon cancer cells treated with Lacticaseibacillus casei undergo apoptosis and release DAMPs indicative of immunogenic cell death. Probiot Antimicrob Prot 2024, 17(6): 4156-4170.
- Aindelis G, Ypsilantis P, Chlichlia K. Alterations in faecal microbiota and elevated levels of intestinal IgA following oral administration of Lacticaseibacillus casei in mice. Probiot Antimicrob Prot 2023, 15(3): 524-534.
- Spyridopoulou K, Aindelis G, Pappa A, Chlichlia K. Anticancer activity of biogenic selenium nanoparticles: apoptotic and immunogenic cell death markers in colon cancer cells. Cancers 2021, 13(21): 5335.
- Spyridopoulou K, Tryfonopoulou E, Aindelis G, Ypsilantis P, Sarafidis C, Kalogirou O, Chlichlia K. Biogenic selenium nanoparticles produced by Lactobacillus casei ATCC393 inhibit colon cancer cell growth in vitro and in vivo. Nanoscale Adv 2021, 3(9): 2516-2528.
- Aindelis G, Tiptiri-Kourpeti A, Lampri E, Spyridopoulou K, Lamprianidou E, Kotsianidis I, Ypsilantis P, Pappa A, Chlichlia K. Immune responses raised in an experimental colon carcinoma model following oral administration of Lactobacillus casei. Cancers 2020, 12(2):368.
- Spyridopoulou K, Aindelis G, Lampri E, Giorgalli M, Lamprianidou E, Kotsianidis I, Tsingotjidou A, Pappa A, Kalogirou O, Chlichlia K. Improving the subcutaneous mouse tumor model by effective manipulation of magnetic nanoparticles-treated implanted cancer cells. Ann Biomed Eng 2018, 46(12): 1975-1987.
| Name | Title | Supervisor | Year | Status |
|---|---|---|---|---|
| Tiptiri-Kourpeti Angeliki | Study of the immune response in mice immunized with genetic vaccines targeting selected cancer antigens | Chlichlia Katerina | 2016 | |
| Spyridopoulou Ekaterini (Katerina) | Design and application of bioactive nanoparticles in cancer prevention and therapy | Chlichlia Katerina | 2018 | |
| Aindelis Georgios | Biological and immunological activities of probiotic microorganisms in models of inflammation and cancer | Chlichlia Katerina | 2020 | |
| Tryfonopoulou Eleni | Investigation of the role of selected coronavirus SARS-CoV-2 proteins on immune responses and immunodiagnosis | Chlichlia Katerina |
No data found.
No data found.
Information
Director
, Post not found (provide a valid id or title).
Department of Molecular Biology & Genetics, School of Health Sciences, Democritus University of Thrace, University Campus-Dragan, Bd. 10-Fotis Kafatos, 68100 Alexandroupolis
